Ranbaxy Malaysia Counts On Hypertension Drug As Major Profit Driver
This article was originally published in PharmAsia News
Executive Summary
Ranbaxy Malaysia anticipates its Covance (losartan) drug for the treatment of hypertension will be a major driver of profits over the next two years